Claim passport · AB-BPC157-US-001
What the evidence for BPC-157 actually shows.
BPC-157 is widely promoted online, but promotion, preclinical findings, and established human clinical evidence are not interchangeable.
Bounded claim
BPC-157 is not an FDA-approved drug, and available evidence does not establish the broad human treatment claims commonly made in online promotion.
What is established
- The FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding.
- FDA materials identify limited safety-related information and potential immunogenicity or impurity concerns.
- Online availability does not establish approval, identity, sterility, safety, or effectiveness.
What remains uncertain
- Clinical effectiveness for the broad injury, gut, recovery, or wellness claims used in promotion.
- The identity and quality of products sold outside regulated drug supply channels.
- Long-term safety, appropriate use, and patient-specific risk.
Source trail
Review and limitations
Editorial review: AminoBrief publishing team, source and scope check completed September 18, 2026. Qualified clinical reviewer: not yet assigned. This page is therefore educational and must not be relied upon for diagnosis, treatment, dosing, sourcing, or product verification.
Correction history: none. Report a correction.